BenevolentAl Therapeutics Pipeline and Triage
Target Validation
Target Validation and Progressability Assessment (TPA)
MATCH
Targets
Tool
Selection
and TPA
'Primary'
Assay
Go/
No Go
'Secondary'
Assay
Deep
Dive
TPA
Validated
Hypothesis
Review
Opportunity to differentiate
Can a new therapeutic against this target
compete relative to the current and future
standard of care?
Freedom to Operate
Exploitable chemistry/biologics space from
an intellectual property perspective
Selectivity
Are there selectivity challenges with
off-targets that are expected to cause
tolerability issues?
Druggability
To what extent is the target amenable to small
molecules, siRNA or mAb therapeutics?
Assayability
Can suitable assays be accessed or developed to
support medicinal chemistry?
Safety Assessment
Are there anticipated safety issues that could be
problematic for onward development?
Benevolent 24
ΑΙView entire presentation